NCT07018297
Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure
At risk: Primary completion moved 31 days later.
See at-risk trials from University of Texas Southwestern Medical Center
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Start date: Aug 2026 to Aug 2028
- Eligibility criteria expanded, about 11 words
- Primary completion pushed from Aug 1, 2028 to Sep 1, 2028
- Publications: details revised at 7 of 7 entries
- Notable Primary completion pushed from Aug 1, 2027 to Aug 1, 2028
- Start date: Feb 2026 to Aug 2026
- Study completion pushed from Sep 1, 2027 to Sep 1, 2028
- Notable Start date: Dec 2025 to Feb 2026v5
- Notable Start date: Sep 15, 2025 to Dec 2025v4
- Notable Start date: Aug 1, 2025 to Sep 15, 2025v3
- Minor Secondary endpoints: details revised at 1 of 3 entries
- Study description expanded, about 1 word
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (3)
Arms and interventions
The practice group randomized to early discharge with subcutaneous furosemide home infusion will begin initiation of subcutaneous furosemide (LASIX-ONYU) with a SQIN-Infusor device prior to discharge from the hospital. Dosing will be based on pre-admission oral furosemide requirements. Those with a home dose of ≤80mg/day oral furosemide will receive 80mg subcutaneous once daily at home and those with \>80mg/day oral furosemide will receive 80mg subcutaneous twice daily at home.
Usual inpatient care with IV furosemide. Discharge timing determined by treating physician per standard practice.
Combination products: Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor
Sites
2 sites in 1 country